Boehringer Ingelheim wants to set the record straight following misleading statements that the British Medical Journal (BMJ) publishedregarding Pradaxar (dabigatran etexilate), as we are concerned that the reporting might put patients at risk of stopping their important stroke preventing medication.

On May, 2014, in one of the largest real world analyses of its kind, the U.S. Food and Drug Administration (FDA) once again reaffirmed the positive efficacy safety profile of Pradaxar when it issued results from this study in clinical practice.

This included more than 134,000 patients, who were 65 years or older and were not monitored.


Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de

Estás comentando usando tu cuenta de Cerrar sesión /  Cambiar )

Google photo

Estás comentando usando tu cuenta de Google. Cerrar sesión /  Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión /  Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión /  Cambiar )

Conectando a %s